Sarcopenia
Conditions
Brief summary
The goal of this observational study is to establish a digital diagnosis and treatment system for sarcopenia, integrating research outcomes into a unified approach encompassing a digital vaccine (early warning screening model), digital drug (intervention model associated with pathogenesis), and digital rehabilitation (preventive system combining early warning and treatment). This aims to create a digital visual tertiary prevention network for sarcopenia. Research aims: Evaluate the effectiveness of the digital vaccine through a cross-sectional epidemiological survey. Establish a specialized cohort for sarcopenia through a longitudinal investigation, implementing the digital drug and digital rehabilitation interventions. Participants will: Engage in screening and assessment based on inclusion and exclusion criteria. Be monitored longitudinally, with tailored interventions for those with muscle atrophy and regular follow-ups for at-risk individuals. Key outcomes will focus on sarcopenia indicators, serum biomarkers, and clinical endpoints such as fracture rates, weakness classification, and quality of life.
Interventions
None listed
Sponsors
Peking Union Medical College Hospital
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
45 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* Age ≥45 years; * meeting sarcopenia diagnostic criteria; * consent to participate in this study
Exclusion criteria
* Age \<45 years; * patients in acute phase of chronic illness; * infectious disease patients; * people who lack of independent mobility; * people who lack of communication or cognitive skills; * people who refusal to participate in this study
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Appendicular skeletal muscle mass index | Through study completion, an average of 6weeks | Defined as muscle mass (Unit: kg/m2) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Hand grip strength | Through study completion, an average of 6weeks | Defined as muscle strength (Unit: kg) |
| Gait speed | Through study completion, an average of 6weeks | Defined as physical performance (Unit: m/s) |
Other
| Measure | Time frame | Description |
|---|---|---|
| Concentration of insulin like growth factor -1(IGF-1) | Through study completion, an average of 6weeks | Serum IGF-1 levels |
| Concentration of interleukin 18 (IL-18) | Through study completion, an average of 6weeks | Serum IL-18 levels |
| Concentration of tumor necrosis factor - α (TNF-α) | Through study completion, an average of 6weeks | Serum TNF-α levels |
| Concentration of TNF-like weak inducer of apoptosis (TWEAK) | Through study completion, an average of 6weeks | Serum TWEAK levels |
| Concentration of insulin | Through study completion, an average of 6weeks | Serum insulin levels |
| Concentration of myostatin | Through study completion, an average of 6weeks | Serum myostatin levels |
| Concentration of chemoattractant protein-1 (MCP-1) | Through study completion, an average of 6weeks | Serum MCP-1 levels |
| Concentration of activin | Through study completion, an average of 6weeks | Serum activin levels |
| Concentration of fibroblast growth factor -19 (FGF-19) | Through study completion, an average of 6weeks | Serum FGF-19 levels |
| Concentration of adiponectin | Through study completion, an average of 6weeks | Serum adiponectin levels |
| Concentration of leptin | Through study completion, an average of 6weeks | Serum leptin levels |
Countries
China
Contacts
Primary ContactYu Kang
Outcome results
None listed